HTR1A | 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
HTR1D | 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
HTR1F | 5-hydroxytryptamine (serotonin) receptor 1F, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
HTR4 | 5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
HTR7 | 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins RAS pathway related proteins
| | | | | Group enriched |
ICAM1 | Intercellular adhesion molecule 1 | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IDE | Insulin-degrading enzyme | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
IFNG | Interferon, gamma | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IKBKB | Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
IMPDH1 | IMP (inosine 5'-monophosphate) dehydrogenase 1 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
IMPDH2 | IMP (inosine 5'-monophosphate) dehydrogenase 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGB3 | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
JAK1 | Janus kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
JAK2 | Janus kinase 2 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
JUN | Jun proto-oncogene | Cancer-related genes FDA approved drug targets Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
KCNA1 | Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNA4 | Potassium voltage-gated channel, shaker-related subfamily, member 4 | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA6 | Potassium voltage-gated channel, shaker-related subfamily, member 6 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCND1 | Potassium voltage-gated channel, Shal-related subfamily, member 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNJ1 | Potassium inwardly-rectifying channel, subfamily J, member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ11 | Potassium inwardly-rectifying channel, subfamily J, member 11 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNJ12 | Potassium inwardly-rectifying channel, subfamily J, member 12 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ8 | Potassium inwardly-rectifying channel, subfamily J, member 8 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK2 | Potassium channel, subfamily K, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK3 | Potassium channel, subfamily K, member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK9 | Potassium channel, subfamily K, member 9 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
KCNMA1 | Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNN4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KDR | Kinase insert domain receptor (a type III receptor tyrosine kinase) | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
KEAP1 | Kelch-like ECH-associated protein 1 | Cancer-related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
KIT | V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Mixed |
LCK | LCK proto-oncogene, Src family tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |